Henry Meds is a telehealth service that sells compounded GLP-1 medication, mostly semaglutide and tirzepatide, for a flat monthly cash price with no insurance involved. The appeal is simple pricing and fast access. The catch is equally simple: what you receive is a compounded product, which is not FDA-approved, and the flat fee only beats insurance if your plan would not have covered a branded drug anyway. Both facts matter before you sign up.
What is Henry Meds selling?
The model bundles a clinical visit, the medication, and shipping into one recurring charge. You complete an intake, a licensed clinician reviews it, and if appropriate a compounding pharmacy prepares and ships the medication. There is no formulary, no prior authorization, and no deductible to satisfy. For someone whose insurance excludes weight management, that removes most of the friction that makes the branded route slow and unpredictable.
The active molecules are the same ones studied in the large semaglutide trials. In STEP 3, semaglutide paired with intensive behavioral therapy produced average weight loss well beyond placebo, and STEP 8 showed weekly semaglutide outperformed daily liraglutide over 68 weeks. Those results describe the branded, FDA-approved product used in the trials, not a compounded copy. That distinction runs through everything below.
What does a compounded product actually mean?
Compounded medication is prepared by a compounding pharmacy rather than manufactured under an approved application. The FDA has been direct that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality the way branded products are, a point laid out plainly in the agency’s compounding questions and answers. That does not make compounding illegitimate. It fills real gaps. But it is not a generic, and treating it as a cheaper Wegovy misreads what you are buying.
The safety picture deserves attention rather than panic. A 2025 pharmacovigilance study using the FDA adverse event reporting system examined reports tied to compounded GLP-1 receptor agonists and found signals worth taking seriously. Separately, a poison control center published a case series of administration errors with compounded semaglutide, many involving patients measuring their own doses from multi-dose vials and drawing up far more than intended. A clinical overview for prescribers on navigating compounded semaglutide reaches a similar conclusion: the molecule may be familiar, but the delivery format and the lack of standardization introduce risks that the branded pen was designed to remove.
How much does Henry Meds really cost?
The advertised figure is a monthly cash price, and the honest way to judge it is against your specific alternative rather than against list price. If your plan covers anti-obesity medication, a covered copay can undercut any cash program, and the flat fee stops being a bargain. If your plan excludes the category, which many commercial and most Medicare plans do, then the comparison is cash program against cash program, and Henry Meds sits in a crowded field.
How does it compare to other telehealth options?
| Provider | Model | What to weigh |
|---|---|---|
| Henry Meds | Flat monthly cash, compounded GLP-1 | Simple pricing, non-FDA-approved product |
| Ro | Telehealth, brand and compounded routes | Broader offerings, more account steps |
| Hims and Hers | Telehealth, subscription based | Widely marketed, watch dose-based pricing |
| Henry Meds vs branded direct | NovoCare, LillyDirect self-pay | Branded, FDA-approved, often higher cash price |
Most of these services look alike at a glance because they share the same underlying molecules and a similar sign-up flow. The differences that matter are pricing transparency, whether the product is branded or compounded, and how much supervision sits behind the prescription. When weighing one flat-fee telehealth practice against another, the comparison of published monthly costs and prescribing structure is where the real decision lives, and as FormBlends explains, a physician-supervised program with a clear flat price is one legitimate option among the named field rather than a magic discount. Ro, Hims and Hers, NovoCare, and LillyDirect each occupy a slightly different spot on that same map.
What are the real drawbacks?
Three stand out. First, the product is not FDA-approved, and the trial evidence people cite when they choose a GLP-1 was generated with the branded version. Second, cash pay means you forgo any insurance benefit you might have, so people with coverage can overpay by choosing convenience. Third, telehealth intake is efficient but thin. A GLP-1 is a serious medication, and the questions a prescriber can ask through a form are not the same as an in-person workup. None of these is disqualifying, but each is a real cost that the clean monthly price hides.
What happens if you stop?
This is the part most sign-up pages skip. GLP-1 medication tends to work while you take it, and the effect fades when you stop. The STEP 1 trial extension tracked participants after they came off semaglutide and documented substantial weight regain over the following year, and the STEP 4 randomized trial showed that continuing the drug maintained loss while switching to placebo reversed it. A flat monthly subscription can quietly become a long-term commitment, and that recurring cost, not the first month, is the number to budget around.
Is it worth it?
For a cash payer with no weight-management coverage who wants predictable pricing and understands they are receiving a compounded product, Henry Meds is a reasonable option. For someone with solid branded coverage, it usually is not worth it, since a covered copay beats paying out of pocket. And for anyone drawn in purely by a low headline figure, the honest advice is to slow down: the medication class works, but it is not casual, and the compounded format carries tradeoffs a branded pen does not. The broader class review of drugs for type 2 diabetes is a useful reminder that these agents are powerful tools with real effects, chosen carefully rather than clicked into a cart.
Key takeaways
- Henry Meds sells compounded semaglutide and tirzepatide at a flat cash price, and compounded drugs are not FDA-approved.
- The flat fee only wins if your plan would not have covered a branded GLP-1.
- Reported dosing and administration errors are a documented risk with compounded, self-measured products.
- Weight regain after stopping is well documented, so the recurring cost is the real cost.
See also: Cuando la Familia Detecta el Cambio: Su Papel en una Reclamación por Lesión Cerebral
Frequently asked questions
What does the Henry Meds monthly price include?
The advertised flat fee generally bundles the clinical visit, the compounded medication, and shipping into one monthly charge with no insurance involved. It is a cash price, so it does not depend on formulary tier or a deductible, but it also does not draw on any insurance benefit you may already have.
Is the medication from Henry Meds the same as Ozempic or Wegovy?
It contains the same active molecule, semaglutide or tirzepatide, but it is a compounded preparation, not the branded product. Compounded drugs are not FDA-approved and have not gone through the approval process behind the branded trials.
Does Henry Meds take insurance?
The core model is cash pay. That is the point of the flat fee, but it means people whose plan would cover a branded GLP-1 may find a covered benefit cheaper than paying out of pocket for a compound.
What are the main risks with compounded GLP-1 medication?
Reported problems include dosing and administration errors, especially with multi-dose vials and patient self-measurement, and less regulatory assurance than an approved product carries. Pharmacovigilance data has flagged adverse events tied to compounded versions.
Who is Henry Meds actually a good fit for?
Cash payers without weight-management coverage who want a predictable monthly cost and are comfortable with a compounded, non-FDA-approved product prescribed under telehealth supervision. People with strong branded coverage usually have a cheaper path.
